C-reactive protein-to-albumin ratio is associated with mortality after transcatheter tricuspid valve repair
Clinical Research in Cardiology · 2025
DOI: 10.1007/s00392-025-02641-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2025. Verfasst von Karl Finke und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department III of Internal Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany. Karl.finke@uk-koeln.d…. Hauptthemen laut MEDLINE: C-Reactive Protein, Tricuspid Valve Insufficiency, Cardiac Catheterization, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.
Abstract (Originalsprache)
Background
Transcatheter tricuspid valve repair (TTVr) is a treatment option for tricuspid regurgitation (TR) in patients with high surgical risk. Given the heterogeneity in clinical benefit, there is a need for markers to assess mortality risk in patients undergoing TTVr. The C-reactive protein (CRP)/albumin ratio (CAR) is a marker of systemic inflammation and reduced nutritional status, which can both occur in TR.
Methods
Consecutive patients undergoing TTVr at a tertiary care center were retrospectively analyzed. Serum CRP and albumin were collected at baseline. Intraprocedural success (IS) was defined according to TVARC criteria. The primary outcome of all-cause mortality was assessed up to 2 years after TTVr.
Results
A total of 215 patients (69% females, median age 80 years) were identified. IS was achieved in 61% of patients. AUC of CAR for 2-year mortality was 0.695, with an optimal threshold of 1.2945 (Youden index) dividing patients in high CAR ( n = 93) and low CAR ( n = 122) groups. In the high CAR group, the primary endpoint occurred more frequently (43% vs 15%, p < 0.001) and significantly higher right atrial pressure, worse renal function, and less IS during TTVr were observed. High CAR was independently associated with an increased mortality risk even when adjusted for renal and liver function, right-ventricular function, and procedural failure (HR 2.188; 95%CI 1.2–3.9; p = 0.011).
Conclusion
Higher CAR reflects patients with advanced right-heart failure and extracardiac organ damage and is associated with mortality after TTVr. CAR is derived from readily available parameters and may be useful additive to established risk scores. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department III of Internal Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany. Karl.finke@uk-koeln.de.
- Faculty of Medicine, Department III of Internal Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany.
- Cardiovascular Research Foundation, New York, United States.
Förderung
- Universitätsklinikum Köln
Zitieren
APA
Finke, K., Marx, L., Althoff, J., Gietzen, T., Schäfer, M., Wrobel, J., von Stein, P., von Stein, J., Körber, M. I., Baldus, S., Pfister, R., & Iliadis, C. (2025). C-reactive protein-to-albumin ratio is associated with mortality after transcatheter tricuspid valve repair. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02641-4
Vancouver
Finke K, Marx L, Althoff J, Gietzen T, Schäfer M, Wrobel J, et al. C-reactive protein-to-albumin ratio is associated with mortality after transcatheter tricuspid valve repair. Clinical Research in Cardiology. 2025. doi:10.1007/s00392-025-02641-4
BibTeX
@article{Finke2025,
author = {Finke, Karl and Marx, Laura and Althoff, Jan and Gietzen, Thorsten and Schäfer, Matthieu and Wrobel, Jan and von Stein, Philipp and von Stein, Jennifer and Körber, Maria Isabel and Baldus, Stephan and Pfister, Roman and Iliadis, Christos},
title = {C-reactive protein-to-albumin ratio is associated with mortality after transcatheter tricuspid valve repair},
journal = {Clinical Research in Cardiology},
year = {2025},
doi = {10.1007/s00392-025-02641-4}
}
EUVIMED